Pfizer reports encouraging early covid-19 vaccine data

An experimental coronavirus vaccine being developed by pharmaceutical giant Pfizer and the German firm BioNTech triggered stronger immune responses in recipients than those seen in people recovering from a natural infection in a small study published online Wednesday.

Coronavirus vaccine research: Scientists pursue RNA to trigger covid immune response

In the global race to beat back the coronavirus pandemic, scientists in Britain, Germany, China and the United States are pushing to develop, and possibly manufacture, vaccines in a completely new way. This promising — but unproven — new generation of vaccine technologies is based on deploying a tiny snip of genetic code called messenger RNA to trigger the immune system. It has never before been approved for use.

Decades of research on an HIV vaccine boosts the bid for one against coronavirus

Those decades of research into HIV have taught scientists an enormous amount about the immune system, honed vaccine technologies now being repurposed against the coronavirus and created a worldwide infrastructure of clinical trial networks that can be pivoted from HIV to the pathogen that causes the disease covid-19.

How to understand your coronavirus test results, from swabs to antibodies

Experts say testing is a vital component to controlling the outbreak, but one test result still isn’t a green light to visit vulnerable friends or family members. The nature of covid-19, the time it takes for someone to develop symptoms and the varied ways the virus affects people make each test a snapshot in time more than a definitive answer.

Draft report predicts coronavirus cases will reach 200,000 a day by June 1

This is a report from a leaked government report. Its is not sure how these predictions are made, and whether it is because of reopening. The white house officials have been relying on other models (than CDC) to make decisions on reopening. The estimates here are based on premature relaxation of restrictions.

How one covid-19 vaccine race went from Oxford to an Italian lab overseeing trials

A lab outside Rome took “seed stock” produced at Oxford. Now U.S. and European officials are showing signs of support. That vaccine, like all the others designed to combat the pandemic, remains unproved. But it is further along in the trial process than the others, and it has turned into the West’s best — and perhaps only — chance to have a viable vaccine before the end of the year.

This coronavirus mutation has taken over the world. Scientists are trying to understand why.

A mutation that seems trivial could be making the virus spread more easily. At least four laboratory experiments suggest that the mutation makes the virus more infectious, although none of that work has been peer-reviewed. Another unpublished study led by scientists at Los Alamos National Laboratory asserts that patients with the G variant actually have more virus in their bodies, making them more likely to spread it to others.